Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534983 | 1.00 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3531445 | 0.84 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3531447 | 0.84 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28436050 | 0.83 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL28959773 | 0.83 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6421503 | 0.82 | SNCA (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6421501 | 0.82 | SNCA (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8631511 | 0.78 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8631504 | 0.78 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL156861 | 0.77 | SNCA (0.64) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | TOPOTARGET UK LIMITED (GB) | 2006-04-13 | — | — | US | disclosed |
| EP-1599449-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004076386-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
| US-5188830-A | Intravenous administration of Factor XIIIa inhibitor | MERCK & CO., INC. (US) | 1993-02-23 | — | — | US | disclosed |
| US-5185149-A | Intravenously administering an acyloxiranecarboxylic acid compound factor XIII inhibitor to lyse clots | MERCK & CO., INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-4968494-A | FACTOR VIIIA INHIBITOR | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0294016-A2 | Factor XIIIa inhibitor compounds useful for thrombolytic therapy | MERCK & CO. INC. (US) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079528-A1 | (E)-3-(1,3-Benzoxazol-2-yl)-N-hydroxy-2-propenamide; Methyl (E)-3-(2-quinolinyl)-2-propenoate; histone deacetylase inhibitors; inflammatory disease; cancer | HDAC1, HDAC11, HDAC5 | HDAC3 6/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | HDAC3 455/4885HDAC4 1869/4885HDAC1 1189/4885 |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC3 7/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.